Last updated on November 2017

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Brief description of study

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Detailed Study Description

The purpose of this study is to evaluate the safety/tolerability and efficacy of INCB039110 in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Clinical Study Identifier: TX9549

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Incyte Corporation Call Center

Research Center
Greenville, SC USA
  Connect »